HRP20050432B1 - Novel medicaments for the treatment of chronic obstructive pulmonary diseases - Google Patents

Novel medicaments for the treatment of chronic obstructive pulmonary diseases

Info

Publication number
HRP20050432B1
HRP20050432B1 HR20050432A HRP20050432A HRP20050432B1 HR P20050432 B1 HRP20050432 B1 HR P20050432B1 HR 20050432 A HR20050432 A HR 20050432A HR P20050432 A HRP20050432 A HR P20050432A HR P20050432 B1 HRP20050432 B1 HR P20050432B1
Authority
HR
Croatia
Prior art keywords
alkyl
treatment
chronic obstructive
obstructive pulmonary
pulmonary diseases
Prior art date
Application number
HR20050432A
Other languages
English (en)
Croatian (hr)
Inventor
Hoenke Christoph
Lustenberger Philipp
Rudolf Klaus
Bouyssou Thierry
Buettner Frank
Konetzki Ingo
Pestel Sabine
Schnapp Andreas
Schollenberger Hermann
Schromm Kurt
Heine Claudia
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050432(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg. filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg.
Publication of HRP20050432A2 publication Critical patent/HRP20050432A2/xx
Publication of HRP20050432B1 publication Critical patent/HRP20050432B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20050432A 2002-11-15 2003-11-11 Novel medicaments for the treatment of chronic obstructive pulmonary diseases HRP20050432B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (de) 2002-11-15 2002-11-15 Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
PCT/EP2003/012565 WO2004045618A2 (de) 2002-11-15 2003-11-11 Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung

Publications (2)

Publication Number Publication Date
HRP20050432A2 HRP20050432A2 (en) 2006-06-30
HRP20050432B1 true HRP20050432B1 (en) 2012-01-31

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050432A HRP20050432B1 (en) 2002-11-15 2003-11-11 Novel medicaments for the treatment of chronic obstructive pulmonary diseases

Country Status (38)

Country Link
EP (2) EP2025338A1 (enrdf_load_stackoverflow)
JP (1) JP4317138B2 (enrdf_load_stackoverflow)
KR (1) KR101092247B1 (enrdf_load_stackoverflow)
CN (3) CN1713914A (enrdf_load_stackoverflow)
AR (2) AR041969A1 (enrdf_load_stackoverflow)
AT (1) ATE430569T1 (enrdf_load_stackoverflow)
AU (1) AU2003285326B2 (enrdf_load_stackoverflow)
BE (1) BE2014C016I2 (enrdf_load_stackoverflow)
BR (1) BRPI0316264B8 (enrdf_load_stackoverflow)
CA (1) CA2506082C (enrdf_load_stackoverflow)
CO (1) CO5570670A2 (enrdf_load_stackoverflow)
CY (2) CY1110500T1 (enrdf_load_stackoverflow)
DE (2) DE10253282A1 (enrdf_load_stackoverflow)
DK (1) DK1562603T3 (enrdf_load_stackoverflow)
EA (1) EA008665B1 (enrdf_load_stackoverflow)
EC (1) ECSP055774A (enrdf_load_stackoverflow)
ES (1) ES2326878T7 (enrdf_load_stackoverflow)
FR (1) FR14C0049I2 (enrdf_load_stackoverflow)
HR (1) HRP20050432B1 (enrdf_load_stackoverflow)
HU (1) HUS1400011I1 (enrdf_load_stackoverflow)
IL (1) IL167900A (enrdf_load_stackoverflow)
LT (1) LTC1562603I2 (enrdf_load_stackoverflow)
LU (1) LU92433I2 (enrdf_load_stackoverflow)
ME (1) ME00354B (enrdf_load_stackoverflow)
MX (1) MXPA05005081A (enrdf_load_stackoverflow)
MY (1) MY136034A (enrdf_load_stackoverflow)
NL (1) NL300650I2 (enrdf_load_stackoverflow)
NO (2) NO334314B1 (enrdf_load_stackoverflow)
NZ (1) NZ540661A (enrdf_load_stackoverflow)
PE (1) PE20040694A1 (enrdf_load_stackoverflow)
PL (1) PL212238B1 (enrdf_load_stackoverflow)
PT (1) PT1562603E (enrdf_load_stackoverflow)
RS (1) RS51607B (enrdf_load_stackoverflow)
SI (1) SI1562603T1 (enrdf_load_stackoverflow)
TW (1) TWI343812B (enrdf_load_stackoverflow)
UA (1) UA81276C2 (enrdf_load_stackoverflow)
WO (1) WO2004045618A2 (enrdf_load_stackoverflow)
ZA (1) ZA200502246B (enrdf_load_stackoverflow)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
EA013157B1 (ru) * 2004-04-22 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
WO2005110990A1 (de) * 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) * 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
RU2442771C2 (ru) 2005-08-08 2012-02-20 Арджента Дискавери Лтд Производные бицикло[2,2,1]гепт-7-иламина и их применения
BRPI0614410A2 (pt) 2005-08-15 2011-03-29 Boehringer Ingelheim Int processo para preparação de betamiméticos
US20070086957A1 (en) * 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
US20070088030A1 (en) * 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
EP2532679B1 (en) 2005-10-21 2017-04-12 Novartis AG Human antibodies against il13 and therapeutic uses
AU2006311060A1 (en) * 2005-11-09 2007-05-18 Boehringer Ingelheim International Gmbh Aerosolformulation for inhalation
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2642239A1 (en) * 2006-02-16 2007-08-23 Boehringer Ingelheim International Gmbh Drug combinations for the treatment of respiratory tract diseases
PE20080142A1 (es) * 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
MY146645A (en) 2006-04-21 2012-09-14 Novartis Ag Purine derivatives for use as adenosin a2a receptor agonists
WO2008017638A1 (de) * 2006-08-07 2008-02-14 Boehringer Ingelheim International Gmbh Enantiomerenreine betaagonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
JP2010508315A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
BRPI0720799A2 (pt) 2007-01-10 2014-03-11 Irm Llc Compostos e composições como inibidores de protease de ativação de canal.
DK2125759T3 (da) * 2007-01-25 2011-09-19 Boehringer Ingelheim Int Fremgangsmåde til fremstilling af betamimetika
DE602008005140D1 (de) 2007-05-07 2011-04-07 Novartis Ag Organische verbindungen
NZ585789A (en) 2007-12-10 2012-03-30 Novartis Ag Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel
CN101910153B (zh) 2008-01-11 2014-01-22 诺华股份有限公司 作为激酶抑制剂的嘧啶类
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
AU2009334597B2 (en) 2008-12-30 2015-07-16 Pulmagen Therapeutics (Inflammation) Limited Sulfonamide compounds for the treatment of respiratory disorders
DK2391366T3 (da) 2009-01-29 2013-01-07 Novartis Ag Substituerede benzimidazoler til behandling af astrocytomer
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
US8497368B2 (en) 2009-08-12 2013-07-30 Novartis Ag Heterocyclic hydrazone compounds
TR201900259T4 (tr) 2009-08-17 2019-02-21 Intellikine Llc Heterosiklik Bileşikler Ve Bunların Kullanımları
JP2013508414A (ja) 2009-10-22 2013-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症および他の慢性疾患の治療のための組成物
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
MX363549B (es) * 2010-09-21 2019-03-26 Intekrin Therapeutics Inc Star Composiciones farmacéuticas sólidas antidiabéticas.
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
ES2551592T3 (es) 2011-02-25 2015-11-20 Novartis Ag Pirazolo[1,5-a]piridinas como inhibidores de TRK
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
BR112014006223A8 (pt) 2011-09-15 2018-01-09 Novartis Ag 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
EP2906218B1 (en) * 2012-10-09 2016-12-14 Boehringer Ingelheim International GmbH Beta-2-adrenoceptor agonist for the treatment of cough
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2015162461A1 (en) 2014-04-24 2015-10-29 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
EA201692140A1 (ru) 2014-04-24 2017-04-28 Новартис Аг Производные аминопиридина в качестве ингибиторов фосфатидилинозитол 3-киназы
JP6433509B2 (ja) 2014-04-24 2018-12-05 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのアミノピラジン誘導体
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
JP6526789B2 (ja) 2014-07-31 2019-06-05 ノバルティス アーゲー 組み合わせ療法
EP3551187B1 (en) 2016-12-12 2021-02-17 Boehringer Ingelheim International GmbH Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
US10800748B2 (en) 2016-12-20 2020-10-13 Inke, S.A. Process for the manufacture of R-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylaminoethyl]-2H-1,4-benzoxazin-3(4H)-one hydrochloride
CN109096218B (zh) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 盐酸奥达特罗晶型a及其制备方法
CN108997248B (zh) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 盐酸奥达特罗晶型b及其制备方法
US20200383960A1 (en) 2019-06-10 2020-12-10 Novartis Ag Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
KR20220052934A (ko) 2019-08-28 2022-04-28 노파르티스 아게 치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도
CN115768404B (zh) * 2020-06-09 2024-11-08 广州谷森制药有限公司 含乌美溴铵和三苯乙酸维兰特罗的药物制剂
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073505A1 (de) * 1981-09-01 1983-03-09 Boehringer Ingelheim Kg Neue Benzo-Heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
EP0321864A2 (de) * 1987-12-19 1989-06-28 Boehringer Ingelheim Kg Neue Ammoniumverbindungen, ihre Herstellung und Verwendung

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0300832A2 (hu) * 2000-04-27 2003-08-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Új, lassú hatású bétamimetikumok, eljárás előállításukra és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073505A1 (de) * 1981-09-01 1983-03-09 Boehringer Ingelheim Kg Neue Benzo-Heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
EP0321864A2 (de) * 1987-12-19 1989-06-28 Boehringer Ingelheim Kg Neue Ammoniumverbindungen, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
HRP20050432A2 (en) 2006-06-30
CN1713914A (zh) 2005-12-28
TWI343812B (en) 2011-06-21
BE2014C016I2 (enrdf_load_stackoverflow) 2023-03-07
TW200423943A (en) 2004-11-16
LU92433I2 (fr) 2014-06-24
BR0316264A (pt) 2005-10-11
ZA200502246B (en) 2006-01-25
BRPI0316264B8 (pt) 2021-05-25
PL212238B1 (pl) 2012-08-31
EA008665B1 (ru) 2007-06-29
EP1562603A2 (de) 2005-08-17
ES2326878T3 (es) 2009-10-21
UA81276C2 (en) 2007-12-25
CY2014032I1 (el) 2015-12-09
EP1562603B3 (de) 2014-01-08
CY1110500T1 (el) 2015-04-29
SI1562603T1 (sl) 2009-10-31
DK1562603T3 (da) 2009-09-07
PE20040694A1 (es) 2004-11-23
ECSP055774A (es) 2005-11-22
CO5570670A2 (es) 2005-10-31
HUS1400011I1 (hu) 2022-02-28
JP4317138B2 (ja) 2009-08-19
AU2003285326A1 (en) 2004-06-15
WO2004045618A2 (de) 2004-06-03
PT1562603E (pt) 2009-06-18
EP2025338A1 (de) 2009-02-18
PL375270A1 (en) 2005-11-28
KR20050075013A (ko) 2005-07-19
MXPA05005081A (es) 2005-07-01
CN101735166A (zh) 2010-06-16
ME00354B (me) 2011-10-10
EA200500715A1 (ru) 2005-12-29
LTC1562603I2 (lt) 2016-12-12
MEP53608A (en) 2011-05-10
KR101092247B1 (ko) 2011-12-12
NZ540661A (en) 2007-12-21
IL167900A (en) 2013-06-27
ATE430569T1 (de) 2009-05-15
NL300650I2 (nl) 2017-11-02
DE10253282A1 (de) 2004-05-27
CA2506082C (en) 2011-06-21
NO2014005I1 (no) 2014-03-10
RS51607B (sr) 2011-08-31
MY136034A (en) 2008-07-31
DE50311502D1 (de) 2009-06-18
BRPI0316264B1 (pt) 2019-04-09
AR087241A2 (es) 2014-03-12
NO20052883L (no) 2005-06-14
AR041969A1 (es) 2005-06-01
AU2003285326B2 (en) 2009-06-04
FR14C0049I1 (enrdf_load_stackoverflow) 2014-08-08
CY2014032I2 (el) 2015-12-09
RS20050361A (sr) 2007-04-10
JP2006508140A (ja) 2006-03-09
ES2326878T7 (es) 2014-03-11
NO334314B1 (no) 2014-02-03
FR14C0049I2 (fr) 2015-07-24
CA2506082A1 (en) 2004-06-03
CN101817800A (zh) 2010-09-01
WO2004045618A3 (de) 2004-09-30
EP1562603B1 (de) 2009-05-06

Similar Documents

Publication Publication Date Title
HRP20050432B1 (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
SE0202463D0 (sv) Novel compounds
MY132106A (en) New pyridazin-3(2h)-one derivatives
NO20061454L (no) Compounds having CRTH2 antagonist activity
NO20060847L (no) Substituert 2-aminotetralin til behandling av depresjon
SE0101387D0 (sv) Novel compounds
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
NO20044995L (no) Heterosykliske forbindelser
MXPA03010142A (es) Nuevos derivados de arilheteroalquilamina.
WO2005051300A3 (en) Bicyclic inhibitors of mek and methods of use thereof
SE0202429D0 (sv) Novel Compounds
DE60333746D1 (de) Thienylverbindungen
SE0203304D0 (sv) Novel Coumpounds
CR7612A (es) Compuestos de fenilsulfonamida sustituida inhibidores de la produccion de beta-amiloide
GB0314967D0 (en) Piperazine derivatives
MX2008001778A (es) Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
RS50229B (sr) Analozi vitamina d3
SE9803773D0 (sv) Compounds
MX2009013003A (es) Derivados de piperidina-amida.
SE0202461D0 (sv) Novel compounds
DE60215918D1 (de) Azofarbstoffe
ATE265423T1 (de) Neue phenylheteroalkylamin-derivate
SE0102640D0 (sv) Novel compounds
ATE416162T1 (de) Naphthamidderivate und deren verwendung

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20181106

Year of fee payment: 16

ODRP Renewal fee for the maintenance of a patent

Payment date: 20191022

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20201102

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20211109

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20221107

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20231111